Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth (Status and Outlook) 2025-2031

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth (Status and Outlook) 2025-2031

The global Amyotrophic Lateral Sclerosis (ALS) Treatment market size is predicted to grow from US$ 343 million in 2025 to US$ 556 million in 2031; it is expected to grow at a CAGR of 8.4% from 2025 to 2031.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

LPI (LP Information)' newest research report, the “Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis (ALS) Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis (ALS) Treatment sales for 2025 through 2031. With Amyotrophic Lateral Sclerosis (ALS) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis (ALS) Treatment industry.

This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis (ALS) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis (ALS) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis (ALS) Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis (ALS) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis (ALS) Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Riluzole
Edaravone (Radicava)
Other

Segmentation by Application:
Hospital
Drugs Store
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.